SOTERA HEALTH COMPANY (SHC) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.05%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.05% | Share-based compensation / revenue. Period ending 2026-06-30. $37.13M ÷ $1.22B × 100 ≈ 3.05% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.22B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 37.13M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.22B | $37.13M | (m) | (m) | (m) | 3.05% | (m) | (m) |
| 2026-03-31 | (m) | $1.19B | $38.03M | (m) | (m) | (m) | 3.20% | (m) | (m) |
| 2025-12-31 | (m) | $1.16B | $30.88M | (m) | (m) | (m) | 2.65% | (m) | (m) |
| 2025-09-30 | (m) | $1.15B | $31.45M | (m) | (m) | (m) | 2.73% | (m) | (m) |
| 2025-06-30 | (m) | $1.12B | $33.29M | (m) | (m) | (m) | 2.96% | (m) | (m) |
| 2025-03-31 | (m) | $1.11B | $35.36M | (m) | (m) | (m) | 3.19% | (m) | (m) |
| 2024-12-31 | (m) | $1.10B | $36.78M | $297.63M | (m) | (m) | 3.34% | (m) | (m) |
| 2024-09-30 | (m) | $1.12B | $36.84M | $314.50M | (m) | (m) | 3.29% | (m) | (m) |
| 2024-06-30 | (m) | $1.10B | $35.42M | $310.10M | (m) | (m) | 3.23% | (m) | (m) |
| 2024-03-31 | (m) | $1.08B | $33.61M | $296.50M | (m) | (m) | 3.12% | (m) | (m) |
| 2023-12-31 | (m) | $1.05B | $32.24M | $276.69M | (m) | (m) | 3.07% | (m) | (m) |
| 2023-09-30 | (m) | $990.64M | $30.29M | $232.84M | (m) | (m) | 3.06% | (m) | (m) |
| 2023-06-30 | (m) | $976.17M | $26.53M | $219.93M | (m) | (m) | 2.72% | (m) | (m) |
| 2023-03-31 | (m) | $987.52M | $23.96M | $228.22M | (m) | (m) | 2.43% | (m) | (m) |
| 2022-12-31 | (m) | $1.00B | $21.21M | $248.35M | (m) | (m) | 2.11% | (m) | (m) |
| 2022-09-30 | (m) | $993.35M | $18.34M | $254.61M | (m) | (m) | 1.85% | (m) | (m) |
| 2022-06-30 | (m) | $970.81M | $17.27M | $257.08M | (m) | (m) | 1.78% | (m) | (m) |
| 2022-03-31 | (m) | $956.08M | $14.96M | $263.86M | (m) | (m) | 1.56% | (m) | (m) |
| 2021-12-31 | (m) | $931.48M | $13.87M | $256.73M | (m) | (m) | 1.49% | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $818.16M | $10.99M | $206.02M | (m) | (m) | 1.34% | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $778.33M | $6.88M | $183.60M | (m) | (m) | 0.88% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Progyny, Inc. (PGNY) | United States | $1.994B | 28.37 |
| agilon health, inc. (AGL) | United States | $1.272B | -7.76 |
| VIEMED HEALTHCARE, INC. (VMD) | United States | $0.336B | 29.92 |
| Park Dental Partners, Inc. (PARK) | United States | $0.094B | |
| BioRestorative Therapies, Inc. (BRTX) | United States | $0.064B | |
| CRYO CELL INTERNATIONAL INC (CCEL) | United States | $0.033B | -11.02 |
| MANGOCEUTICALS, INC. (MGRX) | United States | $0.010B | -0.43 |
| DAVITA INC. (DVA) | United States | $11.147B | 16.80 |